---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-020320"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T21:32:49.764315+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Pharma awards director Dr. Pepose $39,583/mo consulting fee, 32K RSUs and 48K options at $1.79

## Summary
- Monthly consulting fee of $39,583 for Dr. Jay Pepose, an existing director, effective April 11, 2024.
- Grant of 32,000 restricted stock units vesting on April 11, 2025, subject to continued service.
- Options to purchase 48,000 shares at $1.79 (closing price on grant date), vesting in 12 monthly installments.
- Agreement terminates on April 11, 2025, unless extended by mutual written agreement.
- Consulting services in the field of ophthalmology; Dr. Pepose remains an independent contractor.

## SEC filing metadata
- accession: 0001140361-24-020320
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036124020320/0001140361-24-020320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036124020320/ef20027138_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-020320
- JSON: https://secwatch.observer/filing/0001140361-24-020320.json
- Plain text: https://secwatch.observer/filing/0001140361-24-020320.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.